Business Context and Reporting Period
OKYO Pharma Ltd, a foreign private issuer, filed Form 6-K on February 11, 2026. The filing announces a strategic change to its capital raising infrastructure rather than reporting periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate action regarding an equity offering facility.
Material Changes
- ATM Facility Transition: The Company has transitioned its At-The-Market (ATM) equity offering facility from B. Riley Securities Inc. to Leerink Partners LLC.
- Sales Agent Change: Leerink Partners LLC, a healthcare-focused investment bank, is now the designated sales agent.
- Operational Continuity: The change enables the Company to continue selling common shares directly into the market at prevailing prices, subject to market conditions and management discretion.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, forward-looking projections, or a discussion of risks and contingencies. The management commentary is limited to the strategic rationale for selecting a healthcare-focused sales agent to ensure efficient access to capital markets.
Investor Verification Checklist
- Verify the terms of the new sales agreement with Leerink Partners LLC in the attached Exhibit 99.1.
- Confirm the status of the previous ATM facility with B. Riley Securities Inc. to ensure no outstanding obligations remain.
- Review the Company's Form F-3 (Reg. No. 333-293145) to understand the total share availability under the updated ATM program.